Scientists from the American universities of Pittsburgh and Cornell have developed a groundbreaking method to enhance the safety and efficacy of the Bacillus Calmette-Guérin (BCG) tuberculosis vaccine. This new approach involves an intravenous vaccination method that allows the vaccine to self-destruct after completing its task, thereby reducing the risk of accidental self-infection.
The BCG vaccine, primarily used in countries with high tuberculosis prevalence, has been effective in protecting children against severe forms of the disease. However, its traditional intradermal injection offers limited protection for young children and almost none for adults. The new intravenous method, detailed in an article published in Nature Microbiology, has shown promising results in tests on macaque monkeys, significantly improving the vaccine’s effectiveness and safety.
To address safety concerns, the researchers designed a double safety switch. The BCG particles are programmed to self-destruct after exposure to the antibiotic doxycycline or when doxycycline treatment is stopped, ensuring that any remaining mycobacteria cannot cause infection. This mechanism not only protects animals from tuberculosis with the same efficacy as standard BCG vaccination but also allows for faster and safer elimination of the vaccine, even in immunocompromised individuals.
In macaque monkeys, the self-destructing BCG vaccine elicited a more robust immune response and offered better protection against tuberculosis than the traditional intravenous BCG vaccine. None of the monkeys that received the updated vaccine displayed detectable lung inflammation eight weeks after being infected with tuberculosis. Moreover, six out of eight monkeys had no recoverable traces of live tuberculosis, compared to only two out of eight in the standard BCG group.
Despite the challenges ahead in conducting clinical trials to extend the use of the updated vaccine in humans, researchers remain hopeful. Joanne Flynn, a professor of microbiology and molecular genetics at the University of Pittsburgh, expressed optimism that this 'kill switch' BCG strain could limit safety concerns over intravenous vaccine administration and provide a safer and more effective vaccination route for individuals who are immunocompromised.
This discovery marks a significant step forward in the global fight against tuberculosis, offering new hope for better prevention methods in vulnerable populations.
